See every side of every news story

Published 1 year ago • loading... • Updated 1 year ago

AAVantgarde to Present Updated Clinical Data from LUCE-1 Study at EURetina 2025

Summary by The Toronto Star

MILAN, Aug. 28, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced the presentation of updated LUCE-1 clinical data at the 25th European Society of Retina Specialists (EURETINA)…

3 Articles

3 Articles

The Toronto Star

Reposted by

Enid News & Eagle

AAVantgarde to Present Updated Clinical Data from LUCE-1 Study at EURetina 2025

MILAN, Aug. 28, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced the presentation of updated LUCE-1 clinical data at the 25th European Society of Retina Specialists (EURETINA)…

1 year ago·Toronto, Canada

Read Full Article

modernretina.com

Upcoming EURETINA 2025 presentations from Clearside, ZEISS, and Ashvattha

Advancements in retinal therapies and technologies are scheduled to be showcased at EURETINA 2025 from Clearside, ZEISS, and Ashvattha Therapeutics.

1 year ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources3

Leaning Left2Leaning Right0Center0Last Updated1 year agoBias Distribution

100% Left

Bias Distribution

100% of the sources lean Left

100% Left

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Toronto Star broke the news in Toronto, Canada 1 year ago on Thursday, August 28, 2025.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics